Addressing the burden of type 2 diabetes and cardiovascular disease through the management of postprandial hyperglycaemia: An Asian-Pacific perspective and expert recommendations

Diabetes Research and Clinical Practice

Volumn 92, Issue 3, 2011, Pages 312-321

  Sheu, Wayne H H ^a   Rosman, Azhari ^b   Mithal, Ambrish ^c   Chung, Namsik ^d   Lim, Yean Teng ^e   Deerochanawong, Chaicharn ^f   Soewondo, Pradana ^g   Lee, Moon Kyu ^h   Yoon, Kun Ho ⁱ   Schnell, Oliver ^j  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL HEART INSTITUTE   (Malaysia)

^c MEDANTA THE MEDICITY   (India)

^d Yonsei University College of Medicine   (South Korea)

^e Dept Medicine Endocrinol Diabet   (Singapore)

^f RAJAVITHI HOSPITAL   (Thailand)

^g UNIVERSITY OF INDONESIA   (Indonesia)

^h Sungkyunkwan University School of Medicine   (South Korea)

ⁱ The Catholic University of Korea   (South Korea)

^j INSTITUTE OF EPIDEMIOLOGY   (Germany)

more..

Author keywords

Asia; Cardiovascular disease; Postprandial hyperglycaemia; Type 2 diabetes

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLUTAMINE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; TROGLITAZONE; VALSARTAN; VOGLIBOSE;

ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; GLUCOSE BLOOD LEVEL; HEALTH SERVICE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LOWEST INCOME GROUP; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; PREGNANCY DIABETES MELLITUS; PREVALENCE; PRIMARY HEALTH CARE; REVIEW; SCREENING TEST;

ASIA; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA;

EID: 79957995294     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.04.019     Document Type: Review

References (67)

1. World Health Organization. Cardiovascular diseases (CVDs). Fact Sheet No. 317. Updated September 2009. [last accessed 15.11.2010]. http://www.who.int/entity/mediacentre/factsheets/fs317/en/index.html.
2. World Health Organization. Diabetes. Fact Sheet No. 312. November 2009. [last accessed 15.11.2010]. http://www.who.int/entity/mediacentre/factsheets/fs312/en/index.html.
3. International Diabetes Federation. IDF Diabetes Atlas, 4th edition. 2009 [last accessed 15.11.2010]. http://www.diabetesatlas.org/sites/default/files/IDF%20Diabetes%20Atlas%204th%20edition_2.ppt.
4. Institute of Public Health (IPH) The Third National Health and Morbidity Survey (NHMS III) 2006 2008, vol. 2. Ministry of Health, Kuala Lumpur, Malaysia.
5. Chan J.C., Malik V., Jia W., Kadowaki T., Yajnik C.S., Yoon K.H., et al. Diabetes in Asia. Epidemiology, risk factors, and pathophysiology. JAMA 2009, 301:2129-2140.
6. Ueshima H., Sekikawa A., Miura K., Turin T.C., Takashima N., Kita Y., et al. Cardiovascular disease and risk factors in Asia. A selected review. Circulation 2008, 118:2702-2709.
7. Yang W., Lu J., Weng J., Jia W., Ji L., Xiao J., et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362:1090-1101.
8. Chang C.H., Shau W.Y., Jiang Y.D., Li H.Y., Chang T.J., Sheu W.H., et al. Type 2 diabetes prevalence and incidence among adults in Taiwan during 1999-2004: a national health insurance data set study. Diabet Med 2010, 27:636-643.
9. Hu Y., Block G., Sternfeld B., Sowers M. Dietary glycemic load, glycemic index, and associated factors in a multiethnic cohort of midlife women. J Am Coll Nutr 2009, 28:636-647.
10. Henry C.J., Lightowler H.J., Newens K., Sudha V., Radhika G., Sathya R.M., et al. Glycaemic index of common foods tested in the UK and India. Br J Nutr 2008, 99:840-845.
11. Woerle H.J., Pimenta W.P., Meyer C., Gosmanov N.R., Szoke E., Szombathy T., et al. Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values. Arch Intern Med 2004, 164:1627-1632.
12. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003, 26:881-885.
13. Coutinho M., Gerstein H.C., Wang Y., Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233-240.
14. Levitan E.B., Song Y., Ford E.S., Liu S. Is nondiabetic hyperglycaemia a risk factor for cardiovascular disease?. Arch Intern Med 2004, 164:2147-2155.
15. Rodbard H., Blonde L., Braithwaite S.S., Brett E.M., Cobin R.H., Handelsman Y., et al. AACE diabetes Mellitus Clinical Practice Guidelines task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007, 13(Suppl. 1):4-68.
16. Ceriello A., Bortolotti N., Motz E., Pieri C., Marra M., Tonutti L., et al. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 1999, 48:1503-1508.
17. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993, 36:1119-1125.
18. Ceriello A., Quagliaro L., Piconi L., Assaloni R., Da Ros R., Maier A., et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role simvastatin treatment. Diabetes 2004, 55:701-710.
19. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003, 26:1589-1596.
20. Gerich J.E. Clinical significance, pathogenesis, and management of postprandial hyperglycaemia. Arch Intern Med 2003, 163:1306-1316.
21. Fava S. Role of postprandial hyperglycemia in cardiovascular disease. Expert Rev Cardiovasc Ther 2008, 6:859-872.
22. Triggle C.R. The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. Drugs Today 2007, 43:815-826.
23. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924.
24. Leiter L.A., Ceriello A., Davidson J.A., Hanefeld M., Monnier L., Owens D.R. Postprandial glucose regulation: new data and new implications. Clin Ther 2005, 27(Suppl. 2):S42-S56.
25. Avignon A., Radauceanu A., Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997, 20:1822-1826.
26. Shiraiwa T., Kaneto H., Miyatsuka T., Kato K., Yamamoto K., Kawashima A., et al. Postprandial hyperglycaemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care 2005, 28:2806.
27. Hanefeld M., Cagatay M., Petrowitsch T., Neuser D., Petzinna D., Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004, 25:10-16.
28. Wang J.S., Tu S.-T., Lee I.-T., Lin S.-D., Shih-Yi L., Su S.-L., et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev 2011, 27:79-84.
29. Woerle H.J., Neumann C., Zschau S., Tenner S., Irsigler A., Schirra J., et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes: importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007, 77:280-285.
30. Hanefeld M., Fischer S., Julius U., Schulze J., Schwanebeck U., Schmechel H., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996, 39:1577-1583.
31. Cavalot F., Petrelli A., Traversa M., Bonomo K., Fiora E., Conti M., et al. Postprandial glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006, 91:813-819.
32. Barr E.L.M., Zimmet P.Z., Welborn T.A., Jolley D., Magliano D.J., Dunstan D.W., et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance. The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007, 116:151-157.
33. Boyko E.J., Barr E.L., Zimmet P.Z., Shaw J.E. Two-hour glucose predicts the development of hypertension over 5 years: the AusDiab study. J Hum Hypertens 2008, 22:168-176.
34. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999, 354:617-621. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group.
35. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004, 47:385-394. DECODA Study Group.
36. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care 2003, 26:1770-1780. The DECODA Study Group.
37. International Expert Committee International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32:1327-1334.
38. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM trial. Lancet 2002, 359:2072-2077.
39. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494.
40. Esposito K., Giugliano D., Nappo F., Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycaemia in type 2 diabetes mellitus. Circulation 2004, 110:214-219. Campanian Postprandial Hyperglycemia Study Group.
41. Holman R.R., Haffner S.M., McMurray J.J., Bethel M.A., Holzhauer B., et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362:1463-1476. NAVIGATOR Study Group.
42. Raz I., Wilson P.W., Strojek K., Kowalska I., Bozikov V., Gitt A.K., et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009, 32:381-386.
43. Acarbose Cardiovascular Evaluation Trial (ACE) [accessed 05.03.2011]. http://clinicaltrials.gov/ct2/show/NCT00829660.
44. Cheung B.M. The cardiovascular continuum in Asia-a new paradigm for the metabolic syndrome. J Cardiovasc Pharmacol 2005, 46:125-129.
45. Misra A., Khurana L., Isharwal S., Bhardwaj S. South Asian diets and insulin resistance. Br J Nutr 2009, 101:465-473.
46. Burden M.L., Samanta A., Spalding D., Burden A.C. A comparison of the glycaemic and insulinaemic effects of an Asian and European meal. Pract Diabetes Int 1994, 11:208-211.
47. Harada N., Fukushima M., Toyoda K., Mitsui R., Izuka T., Taniguchi A., et al. Factors responsible for elevation of 1-h postchallenge plasma glucose levels in Japanese men. Diabetes Res Clin Pract 2008, 81:284-289.
48. Mitsui R., Fukushima M., Nishi Y., Ueda N., Suzuki H., Taniguchi A., et al. Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese men. Metabolism 2006, 55:53-58.
49. Dong X., Zhou L., Zhai Y., Lu B., Wang D., Shi H., et al. Impaired fasting glucose and the prevalence and severity of angiographic coronary artery disease in high-risk Chinese patients. Metab Clin Exp 2008, 57:24-29.
50. Lin H.-J., Lee B.-C., Ho Y.-L., Lin Y.-H., Chen C.-Y., Hsu H.-C., et al. Postprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the nondiabetic population. Diabetes Care 2009, 32:1721-1726.
51. Chien K.L., Lee B.C., Lin H.J., Hsu H.C., Chen M.F. Association of fasting and post-prandial hyperglycemia on the risk of cardiovascular and all-cause death among non-diabetic Chinese. Diabetes Res Clin Pract 2009, 83:e47-e50.
52. Shimizu H., Uehara Y., Okada S., Mori M. Contribution of fasting and postprandial hyperglycemia to hemoglobin A1c in insulin-treated Japanese diabetic patients. Endocr J 2008, 55:753-756.
53. Gu D., Reynolds K., Duan X., Xin X., Chen J., Wu X., et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia 2003, 46:1190-1198.
54. Yu N.C., Su H.Y., Tsai S.T., Lin B.J., Shiu R.S., Hsieh Y.C., et al. ABC control of diabetes: survey data from National Diabetes Health Promotion Centers in Taiwan. Diabetes Res Clin Pract 2009, 84:194-200.
55. International Diabetes Federation. Self-monitoring of blood glucose in non-insulin treated type 2 diabetes. IDF. 2009 [last accessed 15.11.2010]. http://www.idf.org/webdata/docs/SMBG_EN2.pdf.
56. International Diabetes Federation. Guideline for management of postmeal glucose. IDF. 2007 [last accessed 15.11.2010]. http://www.idf.org/webdata/docs/Guideline_PMG_final.pdf.
57. American Diabetes Association Standards of care in diabetes - 2010. Position statement. Diabetes Care 2010, 33(Suppl. 1):S11-S61.
58. Lonn E.M., Gerstein H.C., Sheridan P., Smith S., Diaz R., et al. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J Am Coll Cardiol 2009, 53:2028-2035. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) and STARR Investigators.
59. Zimmet P., Alberti G. The IDF definition: why we need a global consensus. Diabetes Voice 2006, 51:11-14.
60. Hu Y., Liu W., Chen Y., Zhang M., Wang L. Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 2010, 47(3):231-236.
61. Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators.
62. DeFronzo R.A., Banerji M.A., Bray G.A., Buchanan T.A., Clement S., Henry R.R., et al. Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study. Diabetologia 2010, 53:435-445.
63. Kawamori R., Tajima N., Iwamoto Y., Kashiwagi A., Shimamoto K., Kaku K. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009, 373:1607-1614.
64. Greenfield J.R., Farooqi I.S., Keogh J.M., Henning E., Habib A.M., Blackwood A., et al. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr 2009, 89:106-113.
65. Gerstein H.C., Yusuf S., Riddle M.C., Ryden L., Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008, 1551:26-32. Origin Trial Investigators.
66. Lachin J.M., Christophi C.A., Edelstein S.L., Ehrmann D.A., Hamman R.F., Kahn S.E., et al. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes 2007, 56:1153-1159.
67. Zinman B., Harris S.B., Neuman J., Gerstein H.C., Retnakaran R.R., Raboud J., et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010, 376:103-111.